钾离子竞争性酸阻滞剂的药学特征研究进展  

Progress on pharmaceutical characteristics of potassium-competitive acid blocker

作　　者：王耀振 徐灿 吕顺莉 田泾 张东炜 WANG Yaozhen;XU Can;LV Shunli;TIAN Jing;ZHANG Dongwei(Department of Pharmacy,The First Affiliated Hospital of the Naval Medical University,Shanghai 200433,China;Department of Gastroenterology,The First Affiliated Hospital of the Naval Medical University,Shanghai 200433,China;Department of Pharmacy,The Second Norman Bethune Hospital of Jilin University,Changchun 130041,China;Department of Health Service,The Guard Bureau of the Joint Staff Department of PLA,Beijing 100017,China)

机构地区：[1]海军军医大学第一附属医院药学部,上海200433 [2]海军军医大学第一附属医院消化内科,上海200433 [3]吉林大学白求恩第二医院药学部,吉林长春130041 [4]中央军委联合参谋部警卫局卫生保健处,北京100017

出　　处：《药学实践与服务》2024年第7期278-284,共7页Journal of Pharmaceutical Practice and Service

摘　　要：钾离子竞争性酸阻滞剂(P-CAB)是一类新型抑酸药,通过与H^(+),K^(+)-ATP酶的K^(+)结合位点附近可逆结合,抑制其构象转变而无法完成H^(+)、K^(+)交换,以K^(+)竞争性的方式抑制胃酸分泌。P-CAB独特的结构与新颖的作用机制赋予其优于其他质子泵抑制剂(PPI)的药学特征,使其成为了酸相关性疾病(ARDs)的新选择。就P-CAB的药学特征展开综述。As a new class of acid inhibitors,potassium-competitive acid blocker(P-CAB)inhibits the conformational transition of H^(+),K^(+)-ATPase with subsequent suppression of H^(+),K^(+)exchanging by binding reversibly near the K^(+)binding site of H^(+),K^(+)-ATPase,which results in the inhibition of gastric acid secretion in a K^(+)-competitive manner.The unique structure and novel mechanism of P-CAB contribute to the pharmaceutical characteristics superior to other PPIs,making it a new alternative for acidrelated diseases(ARDs).Progress on pharmaceutical characteristics of P-CAB were reviewed in this paper.

关 键 词：钾离子竞争性酸阻滞剂 酸相关性疾病 研究进展 

分 类 号：R96[医药卫生—药理学]